<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">34930382</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>04</Day></DateCompleted><DateRevised><Year>2022</Year><Month>05</Month><Day>31</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1750-1326</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>1</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>20</Day></PubDate></JournalIssue><Title>Molecular neurodegeneration</Title><ISOAbbreviation>Mol Neurodegener</ISOAbbreviation></Journal><ArticleTitle>TDP-43 Pathology in Alzheimer's Disease.</ArticleTitle><Pagination><StartPage>84</StartPage><MedlinePgn>84</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">84</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1186/s13024-021-00503-x</ELocationID><Abstract><AbstractText>Transactive response DNA binding protein of 43 kDa (TDP-43) is an intranuclear protein encoded by the TARDBP gene that is involved in RNA splicing, trafficking, stabilization, and thus, the regulation of gene expression. Cytoplasmic inclusion bodies containing phosphorylated and truncated forms of TDP-43 are hallmarks of amyotrophic lateral sclerosis (ALS) and a subset of frontotemporal lobar degeneration (FTLD). Additionally, TDP-43 inclusions have been found in up to 57% of Alzheimer's disease (AD) cases, most often in a limbic distribution, with or without hippocampal sclerosis. In some cases, TDP-43 deposits are also found in neurons with neurofibrillary tangles. AD patients with TDP-43 pathology have increased severity of cognitive impairment compared to those without TDP-43 pathology. Furthermore, the most common genetic risk factor for AD, apolipoprotein E4 (APOE4), is associated with increased frequency of TDP-43 pathology. These findings provide strong evidence that TDP-43 pathology is an integral part of multiple neurodegenerative conditions, including AD. Here, we review the biology and pathobiology of TDP-43 with a focus on its role in AD. We emphasize the need for studies on the mechanisms that lead to TDP-43 pathology, especially in the setting of age-related disorders such as AD.</AbstractText><CopyrightInformation>&#xa9; 2021. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Meneses</LastName><ForeName>Axel</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koga</LastName><ForeName>Shunsuke</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>O'Leary</LastName><ForeName>Justin</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dickson</LastName><ForeName>Dennis W</ForeName><Initials>DW</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bu</LastName><ForeName>Guojun</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhao</LastName><ForeName>Na</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-8648-9422</Identifier><AffiliationInfo><Affiliation>Department of Neuroscience, Mayo Clinic, 4500 San Pablo Road, Jacksonville, FL, 32224, USA. Zhao.Na@mayo.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P01 AG026276</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U19 AG069701</GrantID><Acronym>AG</Acronym><Agency>NIA NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>U54 NS110435</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>12</Month><Day>20</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Mol Neurodegener</MedlineTA><NlmUniqueID>101266600</NlmUniqueID><ISSNLinking>1750-1326</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004268">DNA-Binding Proteins</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000598624">TARDBP protein, human</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004268" MajorTopicYN="N">DNA-Binding Proteins</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057180" MajorTopicYN="Y">Frontotemporal Dementia</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057174" MajorTopicYN="Y">Frontotemporal Lobar Degeneration</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016874" MajorTopicYN="N">Neurofibrillary Tangles</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">TARDBP</Keyword><Keyword MajorTopicYN="N">TDP-43</Keyword></KeywordList><CoiStatement>All the authors declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>11</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>12</Month><Day>21</Day><Hour>5</Hour><Minute>48</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>12</Month><Day>22</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34930382</ArticleId><ArticleId IdType="pmc">PMC8691026</ArticleId><ArticleId IdType="doi">10.1186/s13024-021-00503-x</ArticleId><ArticleId IdType="pii">10.1186/s13024-021-00503-x</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>DeTure MA, Dickson DW. The neuropathological diagnosis of Alzheimer's disease. Mol Neurodegener. 2019;14:32.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6679484</ArticleId><ArticleId IdType="pubmed">31375134</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghiso J, Frangione B. Cerebral amyloidosis, amyloid angiopathy, and their relationship to stroke and dementia. J Alzheimers Dis. 2001;3:65&#x2013;73.</Citation><ArticleIdList><ArticleId IdType="pubmed">12214074</ArticleId></ArticleIdList></Reference><Reference><Citation>Guo T, Zhang D, Zeng Y, Huang TY, Xu H, Zhao Y. Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease. Mol Neurodegener. 2020;15:40.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7364557</ArticleId><ArticleId IdType="pubmed">32677986</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Goedert M. Tau protein pathology in neurodegenerative diseases. Trends Neurosci. 1998;21:428&#x2013;433.</Citation><ArticleIdList><ArticleId IdType="pubmed">9786340</ArticleId></ArticleIdList></Reference><Reference><Citation>Spillantini MG, Murrell JR, Goedert M, Farlow M, Klug A, Ghetti B. Mutations in the tau gene (MAPT) in FTDP-17: the family with Multiple System Tauopathy with Presenile Dementia (MSTD) J Alzheimers Dis. 2006;9:373&#x2013;380.</Citation><ArticleIdList><ArticleId IdType="pubmed">16914875</ArticleId></ArticleIdList></Reference><Reference><Citation>McKee AC, Stein TD, Kiernan PT, Alvarez VE. The neuropathology of chronic traumatic encephalopathy. Brain Pathol. 2015;25:350&#x2013;364.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4526170</ArticleId><ArticleId IdType="pubmed">25904048</ArticleId></ArticleIdList></Reference><Reference><Citation>Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol. 2011;10:785&#x2013;796.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3175379</ArticleId><ArticleId IdType="pubmed">21802369</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin F, Ferreira D, Lange C, Dyrba M, Westman E, Buchert R, Teipel SJ, Grothe MJ. Alzheimer's Disease Neuroimaging I: Data-driven FDG-PET subtypes of Alzheimer's disease-related neurodegeneration. Alzheimers Res Ther. 2021;13:49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7896407</ArticleId><ArticleId IdType="pubmed">33608059</ArticleId></ArticleIdList></Reference><Reference><Citation>Vogel JW, Young AL, Oxtoby NP, Smith R, Ossenkoppele R, Strandberg OT, La Joie R, Aksman LM, Grothe MJ, Iturria-Medina Y, et al. Four distinct trajectories of tau deposition identified in Alzheimer's disease. Nat Med. 2021;27:871&#x2013;881.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8686688</ArticleId><ArticleId IdType="pubmed">33927414</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JL, Lee EB, Xie SX, Rennert L, Suh E, Bredenberg C, Caswell C, Van Deerlin VM, Yan N, Yousef A, et al. Neurodegenerative disease concomitant proteinopathies are prevalent, age-related and APOE4-associated. Brain. 2018;141:2181&#x2013;2193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6022546</ArticleId><ArticleId IdType="pubmed">29878075</ArticleId></ArticleIdList></Reference><Reference><Citation>Spina S, La Joie R, Petersen C, Nolan AL, Cuevas D, Cosme C, Hepker M, Hwang JH, Miller ZA, Huang EJ, et al. Comorbid neuropathological diagnoses in early versus late-onset Alzheimer's disease. Brain. 2021;144:2186&#x2013;2198.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8502474</ArticleId><ArticleId IdType="pubmed">33693619</ArticleId></ArticleIdList></Reference><Reference><Citation>Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology. 2007;69:2197&#x2013;2204.</Citation><ArticleIdList><ArticleId IdType="pubmed">17568013</ArticleId></ArticleIdList></Reference><Reference><Citation>Kapasi A, DeCarli C, Schneider JA. Impact of multiple pathologies on the threshold for clinically overt dementia. Acta Neuropathol. 2017;134:171&#x2013;186.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5663642</ArticleId><ArticleId IdType="pubmed">28488154</ArticleId></ArticleIdList></Reference><Reference><Citation>Stover CM, Lynch NJ, Hanson SJ, Windbichler M, Gregory SG, Schwaeble WJ. Organization of the MASP2 locus and its expression profile in mouse and rat. Mamm Genome. 2004;15:887&#x2013;900.</Citation><ArticleIdList><ArticleId IdType="pubmed">15672593</ArticleId></ArticleIdList></Reference><Reference><Citation>Higashi S, Kabuta T, Nagai Y, Tsuchiya Y, Akiyama H, Wada K. TDP-43 associates with stalled ribosomes and contributes to cell survival during cellular stress. J Neurochem. 2013;126:288&#x2013;300.</Citation><ArticleIdList><ArticleId IdType="pubmed">23398327</ArticleId></ArticleIdList></Reference><Reference><Citation>De Conti L, Akinyi MV, Mendoza-Maldonado R, Romano M, Baralle M, Buratti E. TDP-43 affects splicing profiles and isoform production of genes involved in the apoptotic and mitotic cellular pathways. Nucleic Acids Res. 2015;43:8990&#x2013;9005.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4605304</ArticleId><ArticleId IdType="pubmed">26261209</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala YM, De Conti L, Avendano-Vazquez SE, Dhir A, Romano M, D'Ambrogio A, Tollervey J, Ule J, Baralle M, Buratti E, Baralle FE. TDP-43 regulates its mRNA levels through a negative feedback loop. EMBO J. 2011;30:277&#x2013;288.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3025456</ArticleId><ArticleId IdType="pubmed">21131904</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu J, Wu F, Xu W, Shi J, Hu W, Jin N, Qian W, Wang X, Iqbal K, Gong CX, Liu F. TDP-43 suppresses tau expression via promoting its mRNA instability. Nucleic Acids Res. 2017;45:6177&#x2013;6193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5449590</ArticleId><ArticleId IdType="pubmed">28335005</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukushima M, Hosoda N, Chifu K, Hoshino SI. TDP-43 accelerates deadenylation of target mRNAs by recruiting Caf1 deadenylase. FEBS Lett. 2019;593:277&#x2013;287.</Citation><ArticleIdList><ArticleId IdType="pubmed">30520513</ArticleId></ArticleIdList></Reference><Reference><Citation>Alami NH, Smith RB, Carrasco MA, Williams LA, Winborn CS, Han SSW, Kiskinis E, Winborn B, Freibaum BD, Kanagaraj A, et al. Axonal transport of TDP-43 mRNA granules is impaired by ALS-causing mutations. Neuron. 2014;81:536&#x2013;543.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3939050</ArticleId><ArticleId IdType="pubmed">24507191</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawahara Y, Mieda-Sato A. TDP-43 promotes microRNA biogenesis as a component of the Drosha and Dicer complexes. Proc Natl Acad Sci U S A. 2012;109:3347&#x2013;3352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3295278</ArticleId><ArticleId IdType="pubmed">22323604</ArticleId></ArticleIdList></Reference><Reference><Citation>Chew J, Cook C, Gendron TF, Jansen-West K, Del Rosso G, Daughrity LM, Castanedes-Casey M, Kurti A, Stankowski JN, Disney MD, et al. Aberrant deposition of stress granule-resident proteins linked to C9orf72-associated TDP-43 proteinopathy. Mol Neurodegener. 2019;14:9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6377782</ArticleId><ArticleId IdType="pubmed">30767771</ArticleId></ArticleIdList></Reference><Reference><Citation>Sephton CF, Cenik C, Kucukural A, Dammer EB, Cenik B, Han Y, Dewey CM, Roth FP, Herz J, Peng J, et al. Identification of neuronal RNA targets of TDP-43-containing ribonucleoprotein complexes. J Biol Chem. 2011;286:1204&#x2013;1215.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3020728</ArticleId><ArticleId IdType="pubmed">21051541</ArticleId></ArticleIdList></Reference><Reference><Citation>Gu J, Chen F, Iqbal K, Gong CX, Wang X, Liu F. Transactive response DNA-binding protein 43 (TDP-43) regulates alternative splicing of tau exon 10: Implications for the pathogenesis of tauopathies. J Biol Chem. 2017;292:10600&#x2013;10612.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5481566</ArticleId><ArticleId IdType="pubmed">28487370</ArticleId></ArticleIdList></Reference><Reference><Citation>Niblock M, Hortobagyi T, Troakes C, Al-Sarraj S, Spickett C, Jones R, Shaw CE, Gallo JM. Lack of association between TDP-43 pathology and tau mis-splicing in Alzheimer's disease. Neurobiol Aging. 2016;37:45&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4706155</ArticleId><ArticleId IdType="pubmed">26507309</ArticleId></ArticleIdList></Reference><Reference><Citation>Dewey CM, Cenik B, Sephton CF, Johnson BA, Herz J, Yu G. TDP-43 aggregation in neurodegeneration: are stress granules the key? Brain Res. 2012;1462:16&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3372581</ArticleId><ArticleId IdType="pubmed">22405725</ArticleId></ArticleIdList></Reference><Reference><Citation>Khalfallah Y, Kuta R, Grasmuck C, Prat A, Durham HD, Vande Velde C. TDP-43 regulation of stress granule dynamics in neurodegenerative disease-relevant cell types. Sci Rep. 2018;8:7551.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5953947</ArticleId><ArticleId IdType="pubmed">29765078</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim HJ, Raphael AR, LaDow ES, McGurk L, Weber RA, Trojanowski JQ, Lee VM, Finkbeiner S, Gitler AD, Bonini NM. Therapeutic modulation of eIF2alpha phosphorylation rescues TDP-43 toxicity in amyotrophic lateral sclerosis disease models. Nat Genet. 2014;46:152&#x2013;160.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3934366</ArticleId><ArticleId IdType="pubmed">24336168</ArticleId></ArticleIdList></Reference><Reference><Citation>Anderson P, Kedersha N. Stress granules: the Tao of RNA triage. Trends Biochem Sci. 2008;33:141&#x2013;150.</Citation><ArticleIdList><ArticleId IdType="pubmed">18291657</ArticleId></ArticleIdList></Reference><Reference><Citation>Kedersha N, Chen S, Gilks N, Li W, Miller IJ, Stahl J, Anderson P. Evidence that ternary complex (eIF2-GTP-tRNA(i)(Met))-deficient preinitiation complexes are core constituents of mammalian stress granules. Mol Biol Cell. 2002;13:195&#x2013;210.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC65082</ArticleId><ArticleId IdType="pubmed">11809833</ArticleId></ArticleIdList></Reference><Reference><Citation>Baradaran-Heravi Y, Van Broeckhoven C, van der Zee J. Stress granule mediated protein aggregation and underlying gene defects in the FTD-ALS spectrum. Neurobiol Dis. 2020;134:104639.</Citation><ArticleIdList><ArticleId IdType="pubmed">31626953</ArticleId></ArticleIdList></Reference><Reference><Citation>Ayala YM, Zago P, D'Ambrogio A, Xu YF, Petrucelli L, Buratti E, Baralle FE. Structural determinants of the cellular localization and shuttling of TDP-43. J Cell Sci. 2008;121:3778&#x2013;3785.</Citation><ArticleIdList><ArticleId IdType="pubmed">18957508</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang W, Wang L, Lu J, Siedlak SL, Fujioka H, Liang J, Jiang S, Ma X, Jiang Z, da Rocha EL, et al. The inhibition of TDP-43 mitochondrial localization blocks its neuronal toxicity. Nat Med. 2016;22:869&#x2013;878.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4974139</ArticleId><ArticleId IdType="pubmed">27348499</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen-Plotkin AS, Lee VM, Trojanowski JQ. TAR DNA-binding protein 43 in neurodegenerative disease. Nat Rev Neurol. 2010;6:211&#x2013;220.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2892118</ArticleId><ArticleId IdType="pubmed">20234357</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhuo XF, Wang J, Zhang J, Jiang LL, Hu HY, Lu JX. Solid-State NMR Reveals the Structural Transformation of the TDP-43 Amyloidogenic Region upon Fibrillation. J Am Chem Soc. 2020;142:3412&#x2013;3421.</Citation><ArticleIdList><ArticleId IdType="pubmed">32003979</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker AK, Spiller KJ, Ge G, Zheng A, Xu Y, Zhou M, Tripathy K, Kwong LK, Trojanowski JQ, Lee VM. Functional recovery in new mouse models of ALS/FTLD after clearance of pathological cytoplasmic TDP-43. Acta Neuropathol. 2015;130:643&#x2013;660.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5127391</ArticleId><ArticleId IdType="pubmed">26197969</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinarbasi ES, Cagatay T, Fung HYJ, Li YC, Chook YM, Thomas PJ. Active nuclear import and passive nuclear export are the primary determinants of TDP-43 localization. Sci Rep. 2018;8:7083.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5935693</ArticleId><ArticleId IdType="pubmed">29728608</ArticleId></ArticleIdList></Reference><Reference><Citation>Besnard-Guerin C. Cytoplasmic localization of amyotrophic lateral sclerosis-related TDP-43 proteins modulates stress granule formation. Eur J Neurosci. 2020;52:3995&#x2013;4008.</Citation><ArticleIdList><ArticleId IdType="pubmed">32343854</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Donnelly CJ, Haeusler AR, Grima JC, Machamer JB, Steinwald P, Daley EL, Miller SJ, Cunningham KM, Vidensky S, et al. The C9orf72 repeat expansion disrupts nucleocytoplasmic transport. Nature. 2015;525:56&#x2013;61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4800742</ArticleId><ArticleId IdType="pubmed">26308891</ArticleId></ArticleIdList></Reference><Reference><Citation>Chou CC, Zhang Y, Umoh ME, Vaughan SW, Lorenzini I, Liu F, Sayegh M, Donlin-Asp PG, Chen YH, Duong DM, et al. TDP-43 pathology disrupts nuclear pore complexes and nucleocytoplasmic transport in ALS/FTD. Nat Neurosci. 2018;21:228&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5800968</ArticleId><ArticleId IdType="pubmed">29311743</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishimura AL, Zupunski V, Troakes C, Kathe C, Fratta P, Howell M, Gallo JM, Hortobagyi T, Shaw CE, Rogelj B. Nuclear import impairment causes cytoplasmic trans-activation response DNA-binding protein accumulation and is associated with frontotemporal lobar degeneration. Brain. 2010;133:1763&#x2013;1771.</Citation><ArticleIdList><ArticleId IdType="pubmed">20472655</ArticleId></ArticleIdList></Reference><Reference><Citation>Winton MJ, Igaz LM, Wong MM, Kwong LK, Trojanowski JQ, Lee VM. Disturbance of nuclear and cytoplasmic TAR DNA-binding protein (TDP-43) induces disease-like redistribution, sequestration, and aggregate formation. J Biol Chem. 2008;283:13302&#x2013;13309.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2442318</ArticleId><ArticleId IdType="pubmed">18305110</ArticleId></ArticleIdList></Reference><Reference><Citation>Archbold HC, Jackson KL, Arora A, Weskamp K, Tank EM, Li X, Miguez R, Dayton RD, Tamir S, Klein RL, Barmada SJ. TDP43 nuclear export and neurodegeneration in models of amyotrophic lateral sclerosis and frontotemporal dementia. Sci Rep. 2018;8:4606.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5854632</ArticleId><ArticleId IdType="pubmed">29545601</ArticleId></ArticleIdList></Reference><Reference><Citation>Ederle H, Funk C, Abou-Ajram C, Hutten S, Funk EBE, Kehlenbach RH, Bailer SM, Dormann D. Nuclear egress of TDP-43 and FUS occurs independently of Exportin-1/CRM1. Sci Rep. 2018;8:7084.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5935713</ArticleId><ArticleId IdType="pubmed">29728564</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang YJ, Caulfield T, Xu YF, Gendron TF, Hubbard J, Stetler C, Sasaguri H, Whitelaw EC, Cai S, Lee WC, Petrucelli L. The dual functions of the extreme N-terminus of TDP-43 in regulating its biological activity and inclusion formation. Hum Mol Genet. 2013;22:3112&#x2013;3122.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3699067</ArticleId><ArticleId IdType="pubmed">23575225</ArticleId></ArticleIdList></Reference><Reference><Citation>Conicella AE, Zerze GH, Mittal J, Fawzi NL. ALS Mutations Disrupt Phase Separation Mediated by alpha-Helical Structure in the TDP-43 Low-Complexity C-Terminal Domain. Structure. 2016;24:1537&#x2013;1549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5014597</ArticleId><ArticleId IdType="pubmed">27545621</ArticleId></ArticleIdList></Reference><Reference><Citation>Suk TR, Rousseaux MWC. The role of TDP-43 mislocalization in amyotrophic lateral sclerosis. Mol Neurodegener. 2020;15:45.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7429473</ArticleId><ArticleId IdType="pubmed">32799899</ArticleId></ArticleIdList></Reference><Reference><Citation>Jo M, Lee S, Jeon YM, Kim S, Kwon Y, Kim HJ. The role of TDP-43 propagation in neurodegenerative diseases: integrating insights from clinical and experimental studies. Exp Mol Med. 2020;52:1652&#x2013;1662.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8080625</ArticleId><ArticleId IdType="pubmed">33051572</ArticleId></ArticleIdList></Reference><Reference><Citation>de Boer EMJ, Orie VK, Williams T, Baker MR, De Oliveira HM, Polvikoski T, Silsby M, Menon P, van den Bos M, Halliday GM, et al. TDP-43 proteinopathies: a new wave of neurodegenerative diseases. J Neurol Neurosurg Psychiatry. 2020;92(1):86&#x2013;95.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7803890</ArticleId><ArticleId IdType="pubmed">33177049</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnold ES, Ling SC, Huelga SC, Lagier-Tourenne C, Polymenidou M, Ditsworth D, Kordasiewicz HB, McAlonis-Downes M, Platoshyn O, Parone PA, et al. ALS-linked TDP-43 mutations produce aberrant RNA splicing and adult-onset motor neuron disease without aggregation or loss of nuclear TDP-43. Proc Natl Acad Sci U S A. 2013;110:E736&#x2013;E745.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3581922</ArticleId><ArticleId IdType="pubmed">23382207</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreno F, Rabinovici GD, Karydas A, Miller Z, Hsu SC, Legati A, Fong J, Schonhaut D, Esselmann H, Watson C, et al. A novel mutation P112H in the TARDBP gene associated with frontotemporal lobar degeneration without motor neuron disease and abundant neuritic amyloid plaques. Acta Neuropathol Commun. 2015;3:19.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4382926</ArticleId><ArticleId IdType="pubmed">25853458</ArticleId></ArticleIdList></Reference><Reference><Citation>Caroppo P, Camuzat A, Guillot-Noel L, Thomas-Anterion C, Couratier P, Wong TH, Teichmann M, Golfier V, Auriacombe S, Belliard S, et al. Defining the spectrum of frontotemporal dementias associated with TARDBP mutations. Neurol Genet. 2016;2:e80.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4882769</ArticleId><ArticleId IdType="pubmed">27280171</ArticleId></ArticleIdList></Reference><Reference><Citation>Charoniti E, Papastefanopoulou V, Florou-Hatziyiannidou C, Koros C, Stanitsa E, Papatriantafyllou JD, Papageorgiou SG, Kroupis C. TARDBP p.I383V, a recurrent alteration in Greek FTD patients. J Neurol Sci. 2021;428:117566.</Citation><ArticleIdList><ArticleId IdType="pubmed">34271284</ArticleId></ArticleIdList></Reference><Reference><Citation>Rutherford NJ, Zhang YJ, Baker M, Gass JM, Finch NA, Xu YF, Stewart H, Kelley BJ, Kuntz K, Crook RJ, et al. Novel mutations in TARDBP (TDP-43) in patients with familial amyotrophic lateral sclerosis. PLoS Genet. 2008;4:e1000193.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2527686</ArticleId><ArticleId IdType="pubmed">18802454</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng F, Wang H, Liu J, Wang Z, Xu B, Zhao K, Tao X, He Z, Yang F, Huang X. Genetic and clinical features of Chinese sporadic amyotrophic lateral sclerosis patients with TARDBP mutations. Brain Behav. 2021;11:e2312.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8413724</ArticleId><ArticleId IdType="pubmed">34333853</ArticleId></ArticleIdList></Reference><Reference><Citation>Vanden Broeck L, Kleinberger G, Chapuis J, Gistelinck M, Amouyel P, Van Broeckhoven C, Lambert JC, Callaerts P, Dermaut B. Functional complementation in Drosophila to predict the pathogenicity of TARDBP variants: evidence for a loss-of-function mechanism. Neurobiol Aging. 2015;36:1121&#x2013;1129.</Citation><ArticleIdList><ArticleId IdType="pubmed">25442115</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang XL, Tan MS, Tan L, Yu JT. The Role of TDP-43 in Alzheimer's Disease. Mol Neurobiol. 2016;53:3349&#x2013;3359.</Citation><ArticleIdList><ArticleId IdType="pubmed">26081142</ArticleId></ArticleIdList></Reference><Reference><Citation>Brouwers N, Bettens K, Gijselinck I, Engelborghs S, Pickut BA, Van Miegroet H, Montoya AG, Mattheijssens M, Peeters K, De Deyn PP, et al. Contribution of TARDBP to Alzheimer's disease genetic etiology. J Alzheimers Dis. 2010;21:423&#x2013;430.</Citation><ArticleIdList><ArticleId IdType="pubmed">20555136</ArticleId></ArticleIdList></Reference><Reference><Citation>Arai T, Hasegawa M, Akiyama H, Ikeda K, Nonaka T, Mori H, Mann D, Tsuchiya K, Yoshida M, Hashizume Y, Oda T. TDP-43 is a component of ubiquitin-positive tau-negative inclusions in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Biochem Biophys Res Commun. 2006;351:602&#x2013;611.</Citation><ArticleIdList><ArticleId IdType="pubmed">17084815</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Sampathu DM, Kwong LK, Truax AC, Micsenyi MC, Chou TT, Bruce J, Schuck T, Grossman M, Clark CM, et al. Ubiquitinated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Science. 2006;314:130&#x2013;133.</Citation><ArticleIdList><ArticleId IdType="pubmed">17023659</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Bigio EH, Ince PG, Geser F, Neumann M, Cairns NJ, Kwong LK, Forman MS, Ravits J, Stewart H, et al. Pathological TDP-43 distinguishes sporadic amyotrophic lateral sclerosis from amyotrophic lateral sclerosis with SOD1 mutations. Ann Neurol. 2007;61:427&#x2013;434.</Citation><ArticleIdList><ArticleId IdType="pubmed">17469116</ArticleId></ArticleIdList></Reference><Reference><Citation>Feneberg E, Gray E, Ansorge O, Talbot K, Turner MR. Towards a TDP-43-Based Biomarker for ALS and FTLD. Mol Neurobiol. 2018;55:7789&#x2013;7801.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6132775</ArticleId><ArticleId IdType="pubmed">29460270</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann M, Kwong LK, Lee EB, Kremmer E, Flatley A, Xu Y, Forman MS, Troost D, Kretzschmar HA, Trojanowski JQ, Lee VM. Phosphorylation of S409/410 of TDP-43 is a consistent feature in all sporadic and familial forms of TDP-43 proteinopathies. Acta Neuropathol. 2009;117:137&#x2013;149.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2693625</ArticleId><ArticleId IdType="pubmed">19125255</ArticleId></ArticleIdList></Reference><Reference><Citation>Sreedharan J, Blair IP, Tripathi VB, Hu X, Vance C, Rogelj B, Ackerley S, Durnall JC, Williams KL, Buratti E, et al. TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science. 2008;319:1668&#x2013;1672.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7116650</ArticleId><ArticleId IdType="pubmed">18309045</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Neumann M, Baborie A, Sampathu DM, Du Plessis D, Jaros E, Perry RH, Trojanowski JQ, Mann DM, Lee VM. A harmonized classification system for FTLD-TDP pathology. Acta Neuropathol. 2011;122:111&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3285143</ArticleId><ArticleId IdType="pubmed">21644037</ArticleId></ArticleIdList></Reference><Reference><Citation>Mackenzie IR, Neumann M. Subcortical TDP-43 pathology patterns validate cortical FTLD-TDP subtypes and demonstrate unique aspects of C9orf72 mutation cases. Acta Neuropathol. 2020;139:83&#x2013;98.</Citation><ArticleIdList><ArticleId IdType="pubmed">31501924</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampathu DM, Neumann M, Kwong LK, Chou TT, Micsenyi M, Truax A, Bruce J, Grossman M, Trojanowski JQ, Lee VM. Pathological heterogeneity of frontotemporal lobar degeneration with ubiquitin-positive inclusions delineated by ubiquitin immunohistochemistry and novel monoclonal antibodies. Am J Pathol. 2006;169:1343&#x2013;1352.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1780184</ArticleId><ArticleId IdType="pubmed">17003490</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee EB, Porta S, Michael Baer G, Xu Y, Suh E, Kwong LK, Elman L, Grossman M, Lee VM, Irwin DJ, et al. Expansion of the classification of FTLD-TDP: distinct pathology associated with rapidly progressive frontotemporal degeneration. Acta Neuropathol. 2017;134:65&#x2013;78.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5521959</ArticleId><ArticleId IdType="pubmed">28130640</ArticleId></ArticleIdList></Reference><Reference><Citation>Tan RH, Shepherd CE, Kril JJ, McCann H, McGeachie A, McGinley C, Affleck A, Halliday GM. Classification of FTLD-TDP cases into pathological subtypes using antibodies against phosphorylated and non-phosphorylated TDP43. Acta Neuropathol Commun. 2013;1:33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4046675</ArticleId><ArticleId IdType="pubmed">24252630</ArticleId></ArticleIdList></Reference><Reference><Citation>Forman MS, Mackenzie IR, Cairns NJ, Swanson E, Boyer PJ, Drachman DA, Jhaveri BS, Karlawish JH, Pestronk A, Smith TW, et al. Novel ubiquitin neuropathology in frontotemporal dementia with valosin-containing protein gene mutations. J Neuropathol Exp Neurol. 2006;65:571&#x2013;581.</Citation><ArticleIdList><ArticleId IdType="pubmed">16783167</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Irwin DJ, Grossman M, Robinson JL, Toledo JB, Fang L, Van Deerlin VM, Ludolph AC, Lee VM, et al. Sequential distribution of pTDP-43 pathology in behavioral variant frontotemporal dementia (bvFTD) Acta Neuropathol. 2014;127:423&#x2013;439.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3971993</ArticleId><ArticleId IdType="pubmed">24407427</ArticleId></ArticleIdList></Reference><Reference><Citation>Brettschneider J, Del Tredici K, Toledo JB, Robinson JL, Irwin DJ, Grossman M, Suh E, Van Deerlin VM, Wood EM, Baek Y, et al. Stages of pTDP-43 pathology in amyotrophic lateral sclerosis. Ann Neurol. 2013;74:20&#x2013;38.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3785076</ArticleId><ArticleId IdType="pubmed">23686809</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Petrucelli L. Rodent models of TDP-43 proteinopathy: investigating the mechanisms of TDP-43-mediated neurodegeneration. J Mol Neurosci. 2011;45:486&#x2013;499.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3207125</ArticleId><ArticleId IdType="pubmed">21811811</ArticleId></ArticleIdList></Reference><Reference><Citation>Guedes ACB, Santin R, Costa ASR, Reiter KC, Hilbig A, Fernandez LL. Distinct Phospho-TDP-43 brain distribution in two cases of FTD, one associated with ALS. Dement Neuropsychol. 2017;11:249&#x2013;254.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5674668</ArticleId><ArticleId IdType="pubmed">29213521</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinez-Gonzalez L, Rodriguez-Cueto C, Cabezudo D, Bartolome F, Andres-Benito P, Ferrer I, Gil C, Martin-Requero A, Fernandez-Ruiz J, Martinez A, de Lago E. Motor neuron preservation and decrease of in vivo TDP-43 phosphorylation by protein CK-1delta kinase inhibitor treatment. Sci Rep. 2020;10:4449.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7064575</ArticleId><ArticleId IdType="pubmed">32157143</ArticleId></ArticleIdList></Reference><Reference><Citation>Hans F, Eckert M, von Zweydorf F, Gloeckner CJ, Kahle PJ. Identification and characterization of ubiquitinylation sites in TAR DNA-binding protein of 43 kDa (TDP-43) J Biol Chem. 2018;293:16083&#x2013;16099.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6187624</ArticleId><ArticleId IdType="pubmed">30120199</ArticleId></ArticleIdList></Reference><Reference><Citation>Gendron TF, Josephs KA, Petrucelli L. Review: transactive response DNA-binding protein 43 (TDP-43): mechanisms of neurodegeneration. Neuropathol Appl Neurobiol. 2010;36:97&#x2013;112.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3052765</ArticleId><ArticleId IdType="pubmed">20202122</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao J, Wang L, Huntley ML, Perry G, Wang X. Pathomechanisms of TDP-43 in neurodegeneration. J Neurochem. 2018;146(1):7&#x2013;20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6110993</ArticleId><ArticleId IdType="pubmed">29486049</ArticleId></ArticleIdList></Reference><Reference><Citation>Dormann D, Capell A, Carlson AM, Shankaran SS, Rodde R, Neumann M, Kremmer E, Matsuwaki T, Yamanouchi K, Nishihara M, Haass C. Proteolytic processing of TAR DNA binding protein-43 by caspases produces C-terminal fragments with disease defining properties independent of progranulin. J Neurochem. 2009;110:1082&#x2013;1094.</Citation><ArticleIdList><ArticleId IdType="pubmed">19522733</ArticleId></ArticleIdList></Reference><Reference><Citation>Berning BA, Walker AK. The Pathobiology of TDP-43 C-Terminal Fragments in ALS and FTLD. Front Neurosci. 2019;13:335.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6470282</ArticleId><ArticleId IdType="pubmed">31031584</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Q, Yokoshi M, Okada H, Kawahara Y. The cleavage pattern of TDP-43 determines its rate of clearance and cytotoxicity. Nat Commun. 2015;6:6183.</Citation><ArticleIdList><ArticleId IdType="pubmed">25630387</ArticleId></ArticleIdList></Reference><Reference><Citation>Igaz LM, Kwong LK, Chen-Plotkin A, Winton MJ, Unger TL, Xu Y, Neumann M, Trojanowski JQ, Lee VM. Expression of TDP-43 C-terminal Fragments in Vitro Recapitulates Pathological Features of TDP-43 Proteinopathies. J Biol Chem. 2009;284:8516&#x2013;8524.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2659210</ArticleId><ArticleId IdType="pubmed">19164285</ArticleId></ArticleIdList></Reference><Reference><Citation>Farrawell NE, Lambert-Smith IA, Warraich ST, Blair IP, Saunders DN, Hatters DM, Yerbury JJ. Distinct partitioning of ALS associated TDP-43, FUS and SOD1 mutants into cellular inclusions. Sci Rep. 2015;5:13416.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4544019</ArticleId><ArticleId IdType="pubmed">26293199</ArticleId></ArticleIdList></Reference><Reference><Citation>Scotter EL, Vance C, Nishimura AL, Lee YB, Chen HJ, Urwin H, Sardone V, Mitchell JC, Rogelj B, Rubinsztein DC, Shaw CE. Differential roles of the ubiquitin proteasome system and autophagy in the clearance of soluble and aggregated TDP-43 species. J Cell Sci. 2014;127:1263&#x2013;1278.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3953816</ArticleId><ArticleId IdType="pubmed">24424030</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang CC, Bose JK, Majumder P, Lee KH, Huang JT, Huang JK, Shen CK. Metabolism and mis-metabolism of the neuropathological signature protein TDP-43. J Cell Sci. 2014;127:3024&#x2013;3038.</Citation><ArticleIdList><ArticleId IdType="pubmed">24860144</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratti A, Gumina V, Lenzi P, Bossolasco P, Fulceri F, Volpe C, Bardelli D, Pregnolato F, Maraschi A, Fornai F, et al. Chronic stress induces formation of stress granules and pathological TDP-43 aggregates in human ALS fibroblasts and iPSC-motoneurons. Neurobiol Dis. 2020;145:105051.</Citation><ArticleIdList><ArticleId IdType="pubmed">32827688</ArticleId></ArticleIdList></Reference><Reference><Citation>Harrison AF, Shorter J. RNA-binding proteins with prion-like domains in health and disease. Biochem J. 2017;474:1417&#x2013;1438.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5639257</ArticleId><ArticleId IdType="pubmed">28389532</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang K, Daigle JG, Cunningham KM, Coyne AN, Ruan K, Grima JC, Bowen KE, Wadhwa H, Yang P, Rigo F, et al. Stress Granule Assembly Disrupts Nucleocytoplasmic Transport. Cell. 2018;173:958&#x2013;971.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6083872</ArticleId><ArticleId IdType="pubmed">29628143</ArticleId></ArticleIdList></Reference><Reference><Citation>Parker SJ, Meyerowitz J, James JL, Liddell JR, Crouch PJ, Kanninen KM, White AR. Endogenous TDP-43 localized to stress granules can subsequently form protein aggregates. Neurochem Int. 2012;60:415&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pubmed">22306778</ArticleId></ArticleIdList></Reference><Reference><Citation>Bentmann E, Neumann M, Tahirovic S, Rodde R, Dormann D, Haass C. Requirements for stress granule recruitment of fused in sarcoma (FUS) and TAR DNA-binding protein of 43 kDa (TDP-43) J Biol Chem. 2012;287:23079&#x2013;23094.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3391091</ArticleId><ArticleId IdType="pubmed">22563080</ArticleId></ArticleIdList></Reference><Reference><Citation>Mann JR, Gleixner AM, Mauna JC, Gomes E, DeChellis-Marks MR, Needham PG, Copley KE, Hurtle B, Portz B, Pyles NJ, et al. RNA Binding Antagonizes Neurotoxic Phase Transitions of TDP-43. Neuron. 2019;102:321&#x2013;338.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6472983</ArticleId><ArticleId IdType="pubmed">30826182</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang YS, Tsai KJ, Chang YJ, Kao P, Woods R, Kuo PH, Wu CC, Liao JY, Chou SC, Lin V, et al. Full-length TDP-43 forms toxic amyloid oligomers that are present in frontotemporal lobar dementia-TDP patients. Nat Commun. 2014;5:4824.</Citation><ArticleIdList><ArticleId IdType="pubmed">25215604</ArticleId></ArticleIdList></Reference><Reference><Citation>Capitini C, Conti S, Perni M, Guidi F, Cascella R, De Poli A, Penco A, Relini A, Cecchi C, Chiti F. TDP-43 inclusion bodies formed in bacteria are structurally amorphous, non-amyloid and inherently toxic to neuroblastoma cells. PLoS One. 2014;9:e86720.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3907574</ArticleId><ArticleId IdType="pubmed">24497973</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson BS, Snead D, Lee JJ, McCaffery JM, Shorter J, Gitler AD. TDP-43 is intrinsically aggregation-prone, and amyotrophic lateral sclerosis-linked mutations accelerate aggregation and increase toxicity. J Biol Chem. 2009;284:20329&#x2013;20339.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2740458</ArticleId><ArticleId IdType="pubmed">19465477</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang T, Mullane PC, Periz G, Wang J. TDP-43 neurotoxicity and protein aggregation modulated by heat shock factor and insulin/IGF-1 signaling. Hum Mol Genet. 2011;20:1952&#x2013;1965.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3080607</ArticleId><ArticleId IdType="pubmed">21355045</ArticleId></ArticleIdList></Reference><Reference><Citation>Cascella R, Capitini C, Fani G, Dobson CM, Cecchi C, Chiti F. Quantification of the Relative Contributions of Loss-of-function and Gain-of-function Mechanisms in TAR DNA-binding Protein 43 (TDP-43) Proteinopathies. J Biol Chem. 2016;291:19437&#x2013;19448.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5016682</ArticleId><ArticleId IdType="pubmed">27445339</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu-Yesucevitz L, Lin AY, Ebata A, Boon JY, Reid W, Xu YF, Kobrin K, Murphy GJ, Petrucelli L, Wolozin B. ALS-linked mutations enlarge TDP-43-enriched neuronal RNA granules in the dendritic arbor. J Neurosci. 2014;34:4167&#x2013;4174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3960463</ArticleId><ArticleId IdType="pubmed">24647938</ArticleId></ArticleIdList></Reference><Reference><Citation>Leibiger C, Deisel J, Aufschnaiter A, Ambros S, Tereshchenko M, Verheijen BM, Buttner S, Braun RJ. TDP-43 controls lysosomal pathways thereby determining its own clearance and cytotoxicity. Hum Mol Genet. 2018;27:1593&#x2013;1607.</Citation><ArticleIdList><ArticleId IdType="pubmed">29474575</ArticleId></ArticleIdList></Reference><Reference><Citation>Gasset-Rosa F, Lu S, Yu H, Chen C, Melamed Z, Guo L, Shorter J, Da Cruz S, Cleveland DW. Cytoplasmic TDP-43 De-mixing Independent of Stress Granules Drives Inhibition of Nuclear Import, Loss of Nuclear TDP-43, and Cell Death. Neuron. 2019;102:339&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6548321</ArticleId><ArticleId IdType="pubmed">30853299</ArticleId></ArticleIdList></Reference><Reference><Citation>Asakawa K, Handa H, Kawakami K. Optogenetic modulation of TDP-43 oligomerization accelerates ALS-related pathologies in the spinal motor neurons. Nat Commun. 2020;11:1004.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7035286</ArticleId><ArticleId IdType="pubmed">32081878</ArticleId></ArticleIdList></Reference><Reference><Citation>Igaz LM, Kwong LK, Lee EB, Chen-Plotkin A, Swanson E, Unger T, Malunda J, Xu Y, Winton MJ, Trojanowski JQ, Lee VM. Dysregulation of the ALS-associated gene TDP-43 leads to neuronal death and degeneration in mice. J Clin Invest. 2011;121:726&#x2013;738.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3026736</ArticleId><ArticleId IdType="pubmed">21206091</ArticleId></ArticleIdList></Reference><Reference><Citation>Vatsavayai SC, Yoon SJ, Gardner RC, Gendron TF, Vargas JN, Trujillo A, Pribadi M, Phillips JJ, Gaus SE, Hixson JD, et al. Timing and significance of pathological features in C9orf72 expansion-associated frontotemporal dementia. Brain. 2016;139:3202&#x2013;3216.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5790143</ArticleId><ArticleId IdType="pubmed">27797809</ArticleId></ArticleIdList></Reference><Reference><Citation>Nana AL, Sidhu M, Gaus SE, Hwang JL, Li L, Park Y, Kim EJ, Pasquini L, Allen IE, Rankin KP, et al. Neurons selectively targeted in frontotemporal dementia reveal early stage TDP-43 pathobiology. Acta Neuropathol. 2019;137:27&#x2013;46.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6339592</ArticleId><ArticleId IdType="pubmed">30511086</ArticleId></ArticleIdList></Reference><Reference><Citation>Torres P, Ramirez-Nunez O, Romero-Guevara R, Bares G, Granado-Serrano AB, Ayala V, Boada J, Fontdevila L, Povedano M, Sanchis D, et al. Cryptic exon splicing function of TARDBP interacts with autophagy in nervous tissue. Autophagy. 2018;14:1398&#x2013;1403.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6103657</ArticleId><ArticleId IdType="pubmed">29912613</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasaguri H, Chew J, Xu YF, Gendron TF, Garrett A, Lee CW, Jansen-West K, Bauer PO, Perkerson EA, Tong J, et al. The extreme N-terminus of TDP-43 mediates the cytoplasmic aggregation of TDP-43 and associated toxicity in vivo. Brain Res. 1647;2016:57&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5003772</ArticleId><ArticleId IdType="pubmed">27155453</ArticleId></ArticleIdList></Reference><Reference><Citation>McDonald KK, Aulas A, Destroismaisons L, Pickles S, Beleac E, Camu W, Rouleau GA, Vande Velde C. TAR DNA-binding protein 43 (TDP-43) regulates stress granule dynamics via differential regulation of G3BP and TIA-1. Hum Mol Genet. 2011;20:1400&#x2013;1410.</Citation><ArticleIdList><ArticleId IdType="pubmed">21257637</ArticleId></ArticleIdList></Reference><Reference><Citation>Tibshirani M, Zhao B, Gentil BJ, Minotti S, Marques C, Keith J, Rogaeva E, Zinman L, Rouaux C, Robertson J, Durham HD. Dysregulation of chromatin remodelling complexes in amyotrophic lateral sclerosis. Hum Mol Genet. 2017;26:4142&#x2013;4152.</Citation><ArticleIdList><ArticleId IdType="pubmed">28973294</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu EY, Russ J, Cali CP, Phan JM, Amlie-Wolf A, Lee EB. Loss of Nuclear TDP-43 Is Associated with Decondensation of LINE Retrotransposons. Cell Rep. 2019;27:1409&#x2013;1421.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6508629</ArticleId><ArticleId IdType="pubmed">31042469</ArticleId></ArticleIdList></Reference><Reference><Citation>Briese M, Saal-Bauernschubert L, Luningschror P, Moradi M, Dombert B, Surrey V, Appenzeller S, Deng C, Jablonka S, Sendtner M. Loss of Tdp-43 disrupts the axonal transcriptome of motoneurons accompanied by impaired axonal translation and mitochondria function. Acta Neuropathol Commun. 2020;8:116.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7379803</ArticleId><ArticleId IdType="pubmed">32709255</ArticleId></ArticleIdList></Reference><Reference><Citation>Melamed Z, Lopez-Erauskin J, Baughn MW, Zhang O, Drenner K, Sun Y, Freyermuth F, McMahon MA, Beccari MS, Artates JW, et al. Premature polyadenylation-mediated loss of stathmin-2 is a hallmark of TDP-43-dependent neurodegeneration. Nat Neurosci. 2019;22:180&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6348009</ArticleId><ArticleId IdType="pubmed">30643298</ArticleId></ArticleIdList></Reference><Reference><Citation>Klim JR, Williams LA, Limone F. Guerra San Juan I, Davis-Dusenbery BN, Mordes DA, Burberry A, Steinbaugh MJ, Gamage KK, Kirchner R, et al: ALS-implicated protein TDP-43 sustains levels of STMN2, a mediator of motor neuron growth and repair. Nat Neurosci. 2019;22:167&#x2013;179.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7153761</ArticleId><ArticleId IdType="pubmed">30643292</ArticleId></ArticleIdList></Reference><Reference><Citation>Donde A, Sun M, Ling JP, Braunstein KE, Pang B, Wen X, Cheng X, Chen L, Wong PC. Splicing repression is a major function of TDP-43 in motor neurons. Acta Neuropathol. 2019;138:813&#x2013;826.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6802294</ArticleId><ArticleId IdType="pubmed">31332509</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling JP, Pletnikova O, Troncoso JC, Wong PC. TDP-43 repression of nonconserved cryptic exons is compromised in ALS-FTD. Science. 2015;349:650&#x2013;655.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4825810</ArticleId><ArticleId IdType="pubmed">26250685</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun M, Bell W, LaClair KD, Ling JP, Han H, Kageyama Y, Pletnikova O, Troncoso JC, Wong PC, Chen LL. Cryptic exon incorporation occurs in Alzheimer's brain lacking TDP-43 inclusion but exhibiting nuclear clearance of TDP-43. Acta Neuropathol. 2017;133:923&#x2013;931.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5444385</ArticleId><ArticleId IdType="pubmed">28332094</ArticleId></ArticleIdList></Reference><Reference><Citation>James BD, Wilson RS, Boyle PA, Trojanowski JQ, Bennett DA, Schneider JA. TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia. Brain. 2016;139:2983&#x2013;2993.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5091047</ArticleId><ArticleId IdType="pubmed">27694152</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Whitwell JL, Weigand SD, Murray ME, Tosakulwong N, Liesinger AM, Petrucelli L, Senjem ML, Knopman DS, Boeve BF, et al. TDP-43 is a key player in the clinical features associated with Alzheimer's disease. Acta Neuropathol. 2014;127:811&#x2013;824.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4172544</ArticleId><ArticleId IdType="pubmed">24659241</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Murray ME, Whitwell JL, Tosakulwong N, Weigand SD, Petrucelli L, Liesinger AM, Petersen RC, Parisi JE, Dickson DW. Updated TDP-43 in Alzheimer's disease staging scheme. Acta Neuropathol. 2016;131:571&#x2013;585.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5946692</ArticleId><ArticleId IdType="pubmed">26810071</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang HS, Yu L, White CC, Chibnik LB, Chhatwal JP, Sperling RA, Bennett DA, Schneider JA, De Jager PL. Evaluation of TDP-43 proteinopathy and hippocampal sclerosis in relation to APOE epsilon4 haplotype status: a community-based cohort study. Lancet Neurol. 2018;17:773&#x2013;781.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6154505</ArticleId><ArticleId IdType="pubmed">30093249</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Whitwell JL, Tosakulwong N, Weigand SD, Murray ME, Liesinger AM, Petrucelli L, Senjem ML, Ivnik RJ, Parisi JE, et al. TAR DNA-binding protein 43 and pathological subtype of Alzheimer's disease impact clinical features. Ann Neurol. 2015;78:697&#x2013;709.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4623932</ArticleId><ArticleId IdType="pubmed">26224156</ArticleId></ArticleIdList></Reference><Reference><Citation>McAleese KE, Walker L, Erskine D, Thomas AJ, McKeith IG, Attems J. TDP-43 pathology in Alzheimer's disease, dementia with Lewy bodies and ageing. Brain Pathol. 2017;27:472&#x2013;479.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8029292</ArticleId><ArticleId IdType="pubmed">27495267</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Dickson DW, Tosakulwong N, Weigand SD, Murray ME, Petrucelli L, Liesinger AM, Senjem ML, Spychalla AJ, Knopman DS, et al. Rates of hippocampal atrophy and presence of post-mortem TDP-43 in patients with Alzheimer's disease: a longitudinal retrospective study. Lancet Neurol. 2017;16:917&#x2013;924.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5646369</ArticleId><ArticleId IdType="pubmed">28919059</ArticleId></ArticleIdList></Reference><Reference><Citation>Herman AM, Khandelwal PJ, Stanczyk BB, Rebeck GW. Moussa CE: beta-amyloid triggers ALS-associated TDP-43 pathology in AD models. Brain Res. 2011;1386:191&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3073036</ArticleId><ArticleId IdType="pubmed">21376022</ArticleId></ArticleIdList></Reference><Reference><Citation>Amador-Ortiz C, Lin WL, Ahmed Z, Personett D, Davies P, Duara R, Graff-Radford NR, Hutton ML, Dickson DW. TDP-43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease. Ann Neurol. 2007;61:435&#x2013;445.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2677204</ArticleId><ArticleId IdType="pubmed">17469117</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis SA, Gan KA, Dowell JA, Cairns NJ, Gitcho MA. TDP-43 expression influences amyloidbeta plaque deposition and tau aggregation. Neurobiol Dis. 2017;103:154&#x2013;162.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5544914</ArticleId><ArticleId IdType="pubmed">28416393</ArticleId></ArticleIdList></Reference><Reference><Citation>Shih YH, Tu LH, Chang TY, Ganesan K, Chang WW, Chang PS, Fang YS, Lin YT, Jin LW, Chen YR. TDP-43 interacts with amyloid-beta, inhibits fibrillization, and worsens pathology in a model of Alzheimer's disease. Nat Commun. 2020;11:5950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7683652</ArticleId><ArticleId IdType="pubmed">33230138</ArticleId></ArticleIdList></Reference><Reference><Citation>Higashi S, Iseki E, Yamamoto R, Minegishi M, Hino H, Fujisawa K, Togo T, Katsuse O, Uchikado H, Furukawa Y, et al. Concurrence of TDP-43, tau and alpha-synuclein pathology in brains of Alzheimer's disease and dementia with Lewy bodies. Brain Res. 2007;1184:284&#x2013;294.</Citation><ArticleIdList><ArticleId IdType="pubmed">17963732</ArticleId></ArticleIdList></Reference><Reference><Citation>Montalbano M, McAllen S, Cascio FL, Sengupta U, Garcia S, Bhatt N, Ellsworth A, Heidelman EA, Johnson OD, Doskocil S, Kayed R. TDP-43 and Tau Oligomers in Alzheimer's Disease, Amyotrophic Lateral Sclerosis, and Frontotemporal Dementia. Neurobiol Dis. 2020;146:105130.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7703712</ArticleId><ArticleId IdType="pubmed">33065281</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokota O, Davidson Y, Bigio EH, Ishizu H, Terada S, Arai T, Hasegawa M, Akiyama H, Sikkink S, Pickering-Brown S, Mann DM. Phosphorylated TDP-43 pathology and hippocampal sclerosis in progressive supranuclear palsy. Acta Neuropathol. 2010;120:55&#x2013;66.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2901929</ArticleId><ArticleId IdType="pubmed">20512649</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsumata Y, Fardo DW, Kukull WA, Nelson PT. Dichotomous scoring of TDP-43 proteinopathy from specific brain regions in 27 academic research centers: associations with Alzheimer's disease and cerebrovascular disease pathologies. Acta Neuropathol Commun. 2018;6:142.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6299605</ArticleId><ArticleId IdType="pubmed">30567576</ArticleId></ArticleIdList></Reference><Reference><Citation>Tome SO, Vandenberghe R, Ospitalieri S, Van Schoor E, Tousseyn T, Otto M, von Arnim CAF, Thal DR. Distinct molecular patterns of TDP-43 pathology in Alzheimer's disease: relationship with clinical phenotypes. Acta Neuropathol Commun. 2020;8:61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7189555</ArticleId><ArticleId IdType="pubmed">32349792</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Murray ME, Tosakulwong N, Weigand SD, Serie AM, Perkerson RB, Matchett BJ, Jack CR, Knopman DS, Petersen RC, et al. Pathological, imaging and genetic characteristics support the existence of distinct TDP-43 types in non-FTLD brains. Acta Neuropathologica. 2019;137:227&#x2013;238.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6358471</ArticleId><ArticleId IdType="pubmed">30604226</ArticleId></ArticleIdList></Reference><Reference><Citation>Guerrero-Munoz MJ, Castillo-Carranza DL, Krishnamurthy S, Paulucci-Holthauzen AA, Sengupta U, Lasagna-Reeves CA, Ahmad Y, Jackson GR, Kayed R. Amyloid-beta oligomers as a template for secondary amyloidosis in Alzheimer's disease. Neurobiol Dis. 2014;71:14&#x2013;23.</Citation><ArticleIdList><ArticleId IdType="pubmed">25134727</ArticleId></ArticleIdList></Reference><Reference><Citation>LaClair KD, Donde A, Ling JP, Jeong YH, Chhabra R, Martin LJ, Wong PC. Depletion of TDP-43 decreases fibril and plaque beta-amyloid and exacerbates neurodegeneration in an Alzheimer's mouse model. Acta Neuropathol. 2016;132:859&#x2013;873.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5131701</ArticleId><ArticleId IdType="pubmed">27785573</ArticleId></ArticleIdList></Reference><Reference><Citation>Paolicelli RC, Jawaid A, Henstridge CM, Valeri A, Merlini M, Robinson JL, Lee EB, Rose J, Appel S, Lee VM, et al. TDP-43 Depletion in Microglia Promotes Amyloid Clearance but Also Induces Synapse Loss. Neuron. 2017;95:297&#x2013;308.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5519492</ArticleId><ArticleId IdType="pubmed">28669544</ArticleId></ArticleIdList></Reference><Reference><Citation>Bahia VS, Takada LT, Deramecourt V. Neuropathology of frontotemporal lobar degeneration: a review. Dement Neuropsychol. 2013;7:19&#x2013;26.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5619540</ArticleId><ArticleId IdType="pubmed">29213815</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin WL, Dickson DW. Ultrastructural localization of TDP-43 in filamentous neuronal inclusions in various neurodegenerative diseases. Acta Neuropathol. 2008;116:205&#x2013;213.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2706695</ArticleId><ArticleId IdType="pubmed">18607609</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao N, Liu CC, Qiao W, Bu G. Apolipoprotein E, Receptors, and Modulation of Alzheimer's Disease. Biol Psychiatry. 2018;83:347&#x2013;357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5599322</ArticleId><ArticleId IdType="pubmed">28434655</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazaki Y, Zhao N, Caulfield TR, Liu CC, Bu G. Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat Rev Neurol. 2019;15:501&#x2013;518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7055192</ArticleId><ArticleId IdType="pubmed">31367008</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Z, Shue F, Zhao N, Shinohara M, Bu G. APOE2: protective mechanism and therapeutic implications for Alzheimer's disease. Mol Neurodegener. 2020;15:63.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7640652</ArticleId><ArticleId IdType="pubmed">33148290</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao N, Attrebi ON, Ren Y, Qiao W, Sonustun B, Martens YA, Meneses AD, Li F, Shue F, Zheng J, et al. APOE4 exacerbates alpha-synuclein pathology and related toxicity independent of amyloid. Sci Transl Med. 2020;12(529):eaay1809.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8309690</ArticleId><ArticleId IdType="pubmed">32024798</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, Yamada K, Liddelow SA, Smith ST, Zhao L, Luo W, Tsai RM, Spina S, Grinberg LT, Rojas JC, et al. ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549:523&#x2013;527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5641217</ArticleId><ArticleId IdType="pubmed">28959956</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao N, Liu CC, Van Ingelgom AJ, Linares C, Kurti A, Knight JA, Heckman MG, Diehl NN, Shinohara M, Martens YA, et al. APOE epsilon2 is associated with increased tau pathology in primary tauopathy. Nat Commun. 2018;9:4388.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6197187</ArticleId><ArticleId IdType="pubmed">30348994</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu M, He Y, Zhang J, Yang J, Qi J. Co-injection of Abeta1-40 and ApoE4 impaired spatial memory and hippocampal long-term potentiation in rats. Neurosci Lett. 2017;648:47&#x2013;52.</Citation><ArticleIdList><ArticleId IdType="pubmed">28356228</ArticleId></ArticleIdList></Reference><Reference><Citation>Twohig D. Nielsen HM: alpha-synuclein in the pathophysiology of Alzheimer's disease. Mol Neurodegener. 2019;14:23.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6558879</ArticleId><ArticleId IdType="pubmed">31186026</ArticleId></ArticleIdList></Reference><Reference><Citation>Wennberg AM, Tosakulwong N, Lesnick TG, Murray ME, Whitwell JL, Liesinger AM, Petrucelli L, Boeve BF, Parisi JE, Knopman DS, et al. Association of Apolipoprotein E epsilon4 With Transactive Response DNA-Binding Protein 43. JAMA Neurol. 2018;75:1347&#x2013;1354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6248121</ArticleId><ArticleId IdType="pubmed">30422173</ArticleId></ArticleIdList></Reference><Reference><Citation>Vossel KA, Bien-Ly N, Bernardo A, Rascovsky K, Karydas A, Rabinovici GD, Sidhu M, Huang EJ, Miller BL, Huang Y, Seeley WW. ApoE and TDP-43 neuropathology in two siblings with familial FTLD-motor neuron disease. Neurocase. 2013;19:295&#x2013;301.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3655113</ArticleId><ArticleId IdType="pubmed">22512241</ArticleId></ArticleIdList></Reference><Reference><Citation>Koike Y, Sugai A, Hara N, Ito J, Yokoseki A, Ishihara T, Yamagishi T, Tsuboguchi S, Tada M, Ikeuchi T, et al. Age-related demethylation of the TDP-43 autoregulatory region in the human motor cortex. Commun Biol. 2021;4:1107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8455575</ArticleId><ArticleId IdType="pubmed">34548609</ArticleId></ArticleIdList></Reference><Reference><Citation>Nag S, Yu L, Capuano AW, Wilson RS, Leurgans SE, Bennett DA, Schneider JA. Hippocampal sclerosis and TDP-43 pathology in aging and Alzheimer disease. Ann Neurol. 2015;77:942&#x2013;952.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4447563</ArticleId><ArticleId IdType="pubmed">25707479</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Dickson DW, Trojanowski JQ, Jack CR, Boyle PA, Arfanakis K, Rademakers R, Alafuzoff I, Attems J, Brayne C, et al. Limbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report. Brain. 2019;142:1503&#x2013;1527.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6536849</ArticleId><ArticleId IdType="pubmed">31039256</ArticleId></ArticleIdList></Reference><Reference><Citation>Nelson PT, Schmitt FA, Lin Y, Abner EL, Jicha GA, Patel E, Thomason PC, Neltner JH, Smith CD, Santacruz KS, et al. Hippocampal sclerosis in advanced age: clinical and pathological features. Brain. 2011;134:1506&#x2013;1518.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3097889</ArticleId><ArticleId IdType="pubmed">21596774</ArticleId></ArticleIdList></Reference><Reference><Citation>Uchino A, Takao M, Hatsuta H, Sumikura H, Nakano Y, Nogami A, Saito Y, Arai T, Nishiyama K, Murayama S. Incidence and extent of TDP-43 accumulation in aging human brain. Acta Neuropathol Commun. 2015;3:35.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4473839</ArticleId><ArticleId IdType="pubmed">26091809</ArticleId></ArticleIdList></Reference><Reference><Citation>Nag S, Yu L, Boyle PA, Leurgans SE, Bennett DA, Schneider JA. TDP-43 pathology in anterior temporal pole cortex in aging and Alzheimer's disease. Acta Neuropathol Commun. 2018;6:33.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5928580</ArticleId><ArticleId IdType="pubmed">29716643</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsuiji H, Inoue I, Takeuchi M, Furuya A, Yamakage Y, Watanabe S, Koike M, Hattori M, Yamanaka K. TDP-43 accelerates age-dependent degeneration of interneurons. Sci Rep. 2017;7:14972.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5668320</ArticleId><ArticleId IdType="pubmed">29097807</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Davies P, Bevona C, Van Hoeven KH, Factor SM, Grober E, Aronson MK, Crystal HA. Hippocampal sclerosis: a common pathological feature of dementia in very old (&gt; or = 80 years of age) humans. Acta Neuropathol. 1994;88:212&#x2013;221.</Citation><ArticleIdList><ArticleId IdType="pubmed">7810292</ArticleId></ArticleIdList></Reference><Reference><Citation>Amador-Ortiz C, Dickson DW. Neuropathology of hippocampal sclerosis. Handb Clin Neurol. 2008;89:569&#x2013;572.</Citation><ArticleIdList><ArticleId IdType="pubmed">18631779</ArticleId></ArticleIdList></Reference><Reference><Citation>Rademakers R, Eriksen JL, Baker M, Robinson T, Ahmed Z, Lincoln SJ, Finch N, Rutherford NJ, Crook RJ, Josephs KA, et al. Common variation in the miR-659 binding-site of GRN is a major risk factor for TDP43-positive frontotemporal dementia. Hum Mol Genet. 2008;17:3631&#x2013;3642.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2581433</ArticleId><ArticleId IdType="pubmed">18723524</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Deerlin VM, Sleiman PM, Martinez-Lage M, Chen-Plotkin A, Wang LS, Graff-Radford NR, Dickson DW, Rademakers R, Boeve BF, Grossman M, et al. Common variants at 7p21 are associated with frontotemporal lobar degeneration with TDP-43 inclusions. Nat Genet. 2010;42:234&#x2013;239.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2828525</ArticleId><ArticleId IdType="pubmed">20154673</ArticleId></ArticleIdList></Reference><Reference><Citation>Dickson DW, Baker M, Rademakers R. Common variant in GRN is a genetic risk factor for hippocampal sclerosis in the elderly. Neurodegener Dis. 2010;7:170&#x2013;174.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2859236</ArticleId><ArticleId IdType="pubmed">20197700</ArticleId></ArticleIdList></Reference><Reference><Citation>Pao WC, Dickson DW, Crook JE, Finch NA, Rademakers R, Graff-Radford NR. Hippocampal sclerosis in the elderly: genetic and pathologic findings, some mimicking Alzheimer disease clinically. Alzheimer Dis Assoc Disord. 2011;25:364&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3107353</ArticleId><ArticleId IdType="pubmed">21346515</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoki N, Murray ME, Ogaki K, Fujioka S, Rutherford NJ, Rademakers R, Ross OA, Dickson DW. Hippocampal sclerosis in Lewy body disease is a TDP-43 proteinopathy similar to FTLD-TDP Type A. Acta Neuropathologica. 2015;129:53&#x2013;64.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4282950</ArticleId><ArticleId IdType="pubmed">25367383</ArticleId></ArticleIdList></Reference><Reference><Citation>Josephs KA, Mackenzie I, Frosch MP, Bigio EH, Neumann M, Arai T, Dugger BN, Ghetti B, Grossman M, Hasegawa M, et al. LATE to the PART-y. Brain. 2019;142:e47.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6736234</ArticleId><ArticleId IdType="pubmed">31359030</ArticleId></ArticleIdList></Reference><Reference><Citation>Katsumata Y, Abner EL, Karanth S, Teylan MA, Mock CN, Cykowski MD, Lee EB, Boehme KL, Mukherjee S, Kauwe JSK, et al. Distinct clinicopathologic clusters of persons with TDP-43 proteinopathy. Acta Neuropathol. 2020;140:659&#x2013;674.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7572241</ArticleId><ArticleId IdType="pubmed">32797255</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson JL, Porta S, Garrett FG, Zhang PP, Xie SX, Suh E, Van Deerlin VM, Abner EL, Jicha GA, Barber JM, et al. Limbic-predominant age-related TDP-43 encephalopathy differs from frontotemporal lobar degeneration. Brain. 2020;143:2844&#x2013;2857.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7526723</ArticleId><ArticleId IdType="pubmed">32830216</ArticleId></ArticleIdList></Reference><Reference><Citation>Koga S, Sanchez-Contreras M, Josephs KA, Uitti RJ, Graff-Radford N, van Gerpen JA, Cheshire WP, Wszolek ZK, Rademakers R, Dickson DW. Distribution and characteristics of transactive response DNA binding protein 43 kDa pathology in progressive supranuclear palsy. Mov Disord. 2017;32:246&#x2013;255.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5933946</ArticleId><ArticleId IdType="pubmed">28009087</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujishiro H, Uchikado H, Arai T, Hasegawa M, Akiyama H, Yokota O, Tsuchiya K, Togo T, Iseki E, Hirayasu Y. Accumulation of phosphorylated TDP-43 in brains of patients with argyrophilic grain disease. Acta Neuropathol. 2009;117:151&#x2013;158.</Citation><ArticleIdList><ArticleId IdType="pubmed">19039597</ArticleId></ArticleIdList></Reference><Reference><Citation>Uryu K, Nakashima-Yasuda H, Forman MS, Kwong LK, Clark CM, Grossman M, Miller BL, Kretzschmar HA, Lee VM, Trojanowski JQ, Neumann M. Concomitant TAR-DNA-binding protein 43 pathology is present in Alzheimer disease and corticobasal degeneration but not in other tauopathies. J Neuropathol Exp Neurol. 2008;67:555&#x2013;564.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3659339</ArticleId><ArticleId IdType="pubmed">18520774</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwab C, Arai T, Hasegawa M, Yu S, McGeer PL. Colocalization of transactivation-responsive DNA-binding protein 43 and huntingtin in inclusions of Huntington disease. J Neuropathol Exp Neurol. 2008;67:1159&#x2013;1165.</Citation><ArticleIdList><ArticleId IdType="pubmed">19018245</ArticleId></ArticleIdList></Reference><Reference><Citation>Koga S, Kouri N, Walton RL, Ebbert MTW, Josephs KA, Litvan I, Graff-Radford N, Ahlskog JE, Uitti RJ, van Gerpen JA, et al. Corticobasal degeneration with TDP-43 pathology presenting with progressive supranuclear palsy syndrome: a distinct clinicopathologic subtype. Acta Neuropathol. 2018;136:389&#x2013;404.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6309287</ArticleId><ArticleId IdType="pubmed">29926172</ArticleId></ArticleIdList></Reference><Reference><Citation>Koga S, Lin WL, Walton RL, Ross OA, Dickson DW. TDP-43 pathology in multiple system atrophy: colocalization of TDP-43 and alpha-synuclein in glial cytoplasmic inclusions. Neuropathol Appl Neurobiol. 2018;44:707&#x2013;721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6191374</ArticleId><ArticleId IdType="pubmed">29660838</ArticleId></ArticleIdList></Reference><Reference><Citation>Outeiro TF, Koss DJ, Erskine D, Walker L, Kurzawa-Akanbi M, Burn D, Donaghy P, Morris C, Taylor JP, Thomas A, et al. Dementia with Lewy bodies: an update and outlook. Mol Neurodegener. 2019;14:5.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6341685</ArticleId><ArticleId IdType="pubmed">30665447</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar S, Phaneuf D, Cordeau P, Jr, Boutej H, Kriz J, Julien JP. Induction of autophagy mitigates TDP-43 pathology and translational repression of neurofilament mRNAs in mouse models of ALS/FTD. Mol Neurodegener. 2021;16:1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7792109</ArticleId><ArticleId IdType="pubmed">33413517</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, Li Y, Wang C, Tang Y, Mok SA, Tsai RM, Rojas JC, Karydas A, Miller BL, Boxer AL, et al. Promoting tau secretion and propagation by hyperactive p300/CBP via autophagy-lysosomal pathway in tauopathy. Mol Neurodegener. 2020;15:2.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6945522</ArticleId><ArticleId IdType="pubmed">31906970</ArticleId></ArticleIdList></Reference><Reference><Citation>Lynch-Day MA, Mao K, Wang K, Zhao M, Klionsky DJ. The role of autophagy in Parkinson's disease. Cold Spring Harb Perspect Med. 2012;2:a009357.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3312403</ArticleId><ArticleId IdType="pubmed">22474616</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahman MA, Rhim H. Therapeutic implication of autophagy in neurodegenerative diseases. BMB Rep. 2017;50:345&#x2013;354.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5584741</ArticleId><ArticleId IdType="pubmed">28454606</ArticleId></ArticleIdList></Reference><Reference><Citation>Liscic RM, Alberici A, Cairns NJ, Romano M, Buratti E. From basic research to the clinic: innovative therapies for ALS and FTD in the pipeline. Mol Neurodegener. 2020;15:31.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7268618</ArticleId><ArticleId IdType="pubmed">32487123</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>